<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02237612</url>
  </required_header>
  <id_info>
    <org_study_id>4P-08-4</org_study_id>
    <secondary_id>NCI-2014-01848</secondary_id>
    <secondary_id>HS-08-00413-CR004</secondary_id>
    <secondary_id>HS-08-00413</secondary_id>
    <secondary_id>4P-08-4</secondary_id>
    <secondary_id>P30CA014089</secondary_id>
    <nct_id>NCT02237612</nct_id>
  </id_info>
  <brief_title>Diffusion-Weighted MRI in Staging Patients With Localized Prostate Cancer</brief_title>
  <official_title>Diffusion-Weighted MRI for Staging in Localized Prostate Cancer: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies how well diffusion-weighted magnetic resonance imaging
      (MRI) works in staging patients with prostate cancer that has not spread to nearby lymph
      nodes or other parts of the body. New imaging techniques, such as diffusion-weighted MRI, may
      be a less invasive way of predicting the stage and grade of prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the sensitivity and specificity of diffusion-weighted MRI for pathologic T3
      stage prostate cancer using a 3 Tesla (3T) magnet with a surface coil.

      OUTLINE:

      Patients undergo diffusion-weighted MRI of the pelvis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients found to have extracapsular extension and seminal vesicle involvement using Diffusion-Weighted MRI</measure>
    <time_frame>Baseline</time_frame>
    <description>Patients will be imaged using diffusion-weighted MR. Findings will be correlated with histopathologic findings at biopsy and/or prostatectomy.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Adenocarcinoma of the Prostate</condition>
  <condition>Stage IIA Prostate Cancer</condition>
  <condition>Stage IIB Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Diagnostic (diffusion-weighted MRI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo diffusion-weighted MRI of the pelvis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>diffusion-weighted magnetic resonance imaging</intervention_name>
    <description>Undergo diffusion-weighted MRI</description>
    <arm_group_label>Diagnostic (diffusion-weighted MRI)</arm_group_label>
    <other_name>diffusion-weighted MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Diagnostic (diffusion-weighted MRI)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy-documented adenocarcinoma of the prostate which is intermediate or high risk,
             defined as possessing one or more of the following features:

               -  Gleason &gt;= 7

               -  &gt; 50% biopsy cores +

               -  Prostate-specific antigen (PSA) &gt;= 10

          -  Interested in undergoing a radical prostatectomy as definitive management for prostate
             cancer

          -  No clinical or radiographic evidence for distant metastatic disease

               -  In subjects with PSA &lt; 20 no radiographic staging is required in the absence of
                  clinical symptoms for distant metastatic disease; for those with PSA &gt; 20, a bone
                  scan must document lack of concern for bone involvement

        Exclusion Criteria:

          -  Ineligible for surgery due to cardiac, pulmonary, or other major comorbidity factor

          -  History of claustrophobia

          -  Pacemaker or other implanted metal objects which would make subject ineligible for
             MRI, per standard criteria

          -  Unable to give written informed consent
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanya Dorff</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2014</study_first_submitted>
  <study_first_submitted_qc>September 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2014</study_first_posted>
  <last_update_submitted>September 9, 2014</last_update_submitted>
  <last_update_submitted_qc>September 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

